Sergey Yurasov

Eli Lilly (United States) ORCID: 0000-0003-1783-7731

1

h-index

1

Publications

1,263

Citations

Publications

1 shown

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more

2014 The Lancet 1263 citations

Frequent Co-Authors

Edward B. Garon

University of California, Los Angeles

Tudor‐Eliade Ciuleanu

Institute of Oncology Prof. Dr. Ion Chiricuta

Óscar Arrieta

Instituto Nacional de Cancerología

Kumar Prabhash

Tata Memorial Hospital

Konstantinos N. Syrigos

Sotiria General Hospital

Tuncay Göksel

Researcher Info

h-index: 1
Publications: 1
Citations: 1,263
Institution: Eli Lilly (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-1783-7731

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.